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Phase II Trial of Combined Modality Therapy with Myeloid
Growth Factor Support in Patients with Locally Advanced
Non-small Cell Lung Cancer
Rogerio Lilenbaum, MD, Michael Samuels, MD, Michele Taffaro-Neskey, P.A.-C., Mike Cusnir, MD,
Joseph Pizzolato, MD, and Arnold Blaustein, MD
Introduction: To evaluate the efficacy and safety of myeloid
growth factors in patients with locally advanced non-small cell lung
cancer treated with combined modality therapy (CMT).
Methods: Patients with stage IIIA/B non-small cell lung cancer,
performance status 0 to 1, and forced expiratory volume in 1 second
1.5, received cisplatin 75 mg/m2 on day 1  etoposide 80 mg/m2
on days 1 to 3 every 3 weeks for 2 cycles concurrent with thoracic
radiotherapy to 61 Gy. filgrastim 5 mcg/kg/d was administered for
10 days beginning on day 4 of each chemotherapy cycle. Patients
without progression received docetaxel 75 mg/m2 every 21 days for
3 cycles with peg-filgrastim 6 mg on day 2. The primary end point
was a 50% reduction in the incidence of grade 3⁄4 neutropenia
compared with historical controls.
Results: A total of 26 eligible patients were enrolled. Median age
was 67, 76% were men, and 58% had stage IIIA. Gr3/4 neutropenia
during CMT was 19.2% and 3.8%, respectively. There were no
episodes of febrile neutropenia. Gr4 thrombocytopenia was 15.4%
with 2 patients requiring transfusions. Gr3 esophagitis was noted in
7.7% and Gr 3⁄4 pneumonitis in 21.6% of patients. No patients died
of treatment-related toxicities. Dose reductions/delays occurred in
3.8% of patients during CMT. Median progression-free survival and
median survival were 10.7 and 27.6 months, respectively. The 1-
and 2-year survival rates were 61.5% and 46.2%, respectively.
Conclusions: Our data suggest that the addition of filgrastim to
CMT is safe and effective. The rate of grade 3⁄4 toxicities, including
febrile neutropenia, compares favorably to previous trials using a
similar regimen. Dose intensity is maintained. This strategy merits
further evaluation.
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(J Thorac Oncol. 2010;5: 837–840)
Approximately 35% of patients diagnosed with non-smallcell lung cancer (NSCLC) have locally advanced disease
at presentation. The standard of care in this setting is com-
bined modality therapy (CMT), with chemotherapy (CT) and
thoracic radiotherapy (TRT) delivered concurrently. Out-
comes include a median survival of 18 to 24 months, with
approximately 15 to 30% of patients expected to achieve
long-term disease-free survival.1
One of the principal toxicities of CMT is myelosup-
pression. Neutropenia is common and often severe, leading to
febrile episodes, hospitalizations, and occasionally death.
Furthermore, neutropenia may lead to dose reductions and/or
dose delays, which may compromise therapeutic outcome in
a potentially curable setting. In patients with advanced dis-
ease, these complications can be mitigated by the use of
myeloid growth factors, such as filgrastim and peg-filgras-
tim.2 However, these agents are not approved for use in
combination with TRT.
A previous phase III randomized trial by the South
West Oncology Group (SWOG) in limited-stage small-cell
lung cancer tested CT and TRT with or without sargramostim
(granulocyte-macrophage colony stimulating factor), and
showed worse thrombocytopenia and more frequent nonhe-
matological adverse events (including toxic deaths) in the
growth factor arm.3 This observation supported early theo-
retical concerns that growth factors may release megakaryo-
cytes that are more radiosensitive than nonrecruited marrow
progenitors.2 Since then, the use of myeloid growth factors
has not been permitted during CMT and has not been revis-
ited despite significant improvements in TRT techniques and
supportive care over the last decade.
At the time this study was conceived, a phase II trial by
SWOG had shown unprecedented results in patients with
stage IIIB NSCLC treated with cisplatin and etoposide con-
currently with TRT followed by three cycles of consolidation
docetaxel.4 Hematologic toxicity included grade 3⁄4 neutrope-
nia in 74% of the patients, including two infection-related
deaths. A subsequent phase III trial by the Hoosier Oncology
Group (HOG), using the same CMT, showed no benefit and
worse toxicity for consolidation docetaxel.5 Grade 3⁄4 neutro-
penia and febrile neutropenia rates during CMT were 32%
and 9.9%, respectively. In both trials, myeloid growth factors
were not allowed during CMT.
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Therefore, measures to diminish neutropenia would
facilitate the delivery of CMT and maintain dose intensity,
avoiding important clinical complications and possibly lead-
ing to better outcomes. The main objective of this trial was to
determine the safety and efficacy of the addition of filgrastim
to CMT and peg-filgrastim to consolidation CT.
PATIENTS AND METHODS
Eligibility
Patients with histologic or cytologic confirmation of
unresectable stage IIIA/B NSCLC, defined as: N2 disease by
biopsy, PET-avidity, or nodes  2 cm; N3 disease by biopsy,
PET-avidity, or contralateral/supraclavicular nodes  2 cm;
T4 disease by documentation of invasion of adjacent struc-
tures by radiologist or surgeon. Additional eligibility criteria
included performance status 0–1; measurable disease; forced
expiratory volume in 1 second (FEV-1) 1.5 L or if1.5 L,
a predicted FEV1of the contralateral lung of 800 ml based
on the quantitative split function testing; and adequate bone
marrow, kidney and liver function. Patients with were ex-
cluded if they had prior CT or radiotherapy; malignant pleural
or pericardial effusion; previous malignancy other than basal
or squamous carcinoma of the skin or carcinoma in situ of the
cervix, or any other cancer for which the patient had been
disease free for 5 years. Patients eligible for consolidation
had to have completed CMT within 4 to 8 weeks and have
achieved stable disease, partial or complete response and
maintain same requirements as the initial eligibility. The
study was approved by the Institutional Review Board and all
patients signed informed consent.
Treatment Plan
Patients were treated with cisplatin at 75 mg/m2 on
days 1 and 22, and etoposide 80 mg/m2 on days 1 to 3 and 22
to 24, after appropriate hydration and antiemetics. Filgrastim
was administered at a dose of 5 mcg SC daily on days 4 to 13
and 25 to 34. TRT was given as 1.8 Gy daily to 41.4 to 45 Gy
to initial fields, followed by a boost to a total dose of 61 to
61.4 Gy beginning on day 1 (Figure 1). The initial radiation
field was delivered to a volume that included the primary
tumor, ipsilateral hilar nodes, and the ipsilateral mediastinal
nodes according to the location of the primary. Elective
treatment of supraclavicular nodes was not allowed initially,
though the trial was later amended to permit elective supra-
clavicular radiotherapy at the discretion of the treating radi-
ation oncologist. The boost volume included the primary
tumor and known involved lymph nodes measuring 1 cm
on initial CT plus a 1.5 to 2 cm margin. No more than 35%
of total lung volume, minus the primary tumor and lymph
nodes greater than 1 cm in diameter, received more than 20
Gy. CT-planning was required, but intensity-modulated ra-
diotherapy was not permitted on the trial.
Patients were reevaluated between 4 and 6 weeks after
CMT. Those without progression were treated with consoli-
dation docetaxel at 75 mg/m2 every 3 weeks for 3 cycles.
Peg-filgrastim was administered at a dose of 6 mg SC on day
2 of each cycle.
Dose modifications were permitted once during CMT
to cisplatin 60 mg/m2 and etoposide 60 mg/m2/d, and twice
during consolidation to 60 mg/m2 and 45 mg/m2 for febrile
neutropenia, grade 4 neutropenia lasting longer than 7 days,
grade 4 thrombocytopenia, grade 4 emesis, grade 3 diar-
rhea, grade 2 neuropathy, grade 3 fluid retention, abnormal
liver function, and grade 3 stomatitis. Treatment was de-
layed for grade 3⁄4 toxicity until it resolved to at least grade 1,
then reinitiated with one dose level reduction. Response
criteria were evaluated according to the RECIST criteria.
Statistical Design
The primary end point was the incidence of grades 3
and 4 neutropenia during CMT and consolidation CT. As-
suming a 74% incidence of grades 3 to 4 neutropenia in the
historical control (SWOG 9504), with a power of 90%,
approximately 28 patients were needed to detect a 50%
reduction in grades 3 to 4 neutropenia. The key secondary
endpoints were incidence of grade 4 thrombocytopenia; inci-
dence of toxic deaths caused by thrombotic/embolic events or
pneumonitis; and incidence of grade 3⁄4 esophagitis, as ob-
served in the historical control (SWOG 9504), with 0%, 2%
and 17%, respectively. Efficacy parameters included response
rate after CMT and after consolidation, progression-free sur-
vival, median, and 1-year survival. The progress of the study
with an emphasis on safety analysis was monitored by the
principal investigators and reported on a regular basis to the
FIGURE 1. Treatment schema.
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institutional review board. Appropriate safeguards were in
place to monitor toxicities throughout the conduct of the trial.
The study was to be terminated if 3 of 10 or6 of 20 subjects
had grade 4 thrombocytopenia requiring platelet transfusion,
or if 1 of 10 or 2 of 20 subjects had toxic deaths caused by
thrombotic/embolic events or pneumonitis other severe un-
expected toxicities.
RESULTS
Patient Characteristics and Treatment
Compliance
Twenty-six patients were enrolled between March 2004
and March 2009. Accrual became difficult after the publica-
tion of the HOG trial and the principal investigators decided
to close the study because of ethical concerns about the
template regimen. Patient characteristics are shown in Ta-
ble 1. Median age was 67 (range, 50–81), 76% were men,
and 38% had performance status 0. Fifteen patients had stage
IIIA and 11 had stage IIIB disease. Histologic subtype re-
vealed 42.3% adenocarcinoma. All patients had FEV1  1.5
L and all had a PET scan at baseline.
All patients completed CMT with 2 dose delays and 1
dose reduction as per protocol. Of the 23 patients treated with
at least one cycle of consolidation docetaxel, 14 received all
3 cycles; 8 received 2 cycles; and 1 received 1 cycle. Three
patients had progressive disease after CMT and did not
receive consolidation. Reasons for discontinuation of do-
cetaxel were grades 2 and 3⁄4 pneumonitis in 4 and 2 patients,
respectively, in whom the third cycle of consolidation was
withheld; and fluid retention in one patient.
Toxicity
The main toxicities are summarized in Table 2. During
CMT, grade 3 neutropenia was observed in five patients
(19.2%), whereas one patient (3.8%) had grade 4 neutropenia.
No patient had febrile neutropenia. Grade 4 thrombocytope-
nia was noted in 4 patients (15.4%), with platelet counts ranging
from 9,000 to 24,000. Two patients required a platelet transfu-
sion. No bleeding was observed. Grade 3 anemia was noted in
two patients (7.7%) and two required transfusions. Nonhemato-
logic toxicities during CMT were mild to moderate, including
grade 3 esophagitis in two patients (7.7%).
Among the 23 patients treated with consolidation do-
cetaxel, hematologic toxicity was mild, with only one episode
of grade 3 anemia but no grade 3⁄4 neutropenia or thrombo-
cytopenia. Pneumonitis was grade 3 in four patients (17.3%),
and grade 4 in one patient (4.3%). No patient died of treat-
ment-related toxicities.
Efficacy
Response after CMT for all 26 eligible patients (inten-
tion to treat) was 57.5% (95% CI, 37.9–76) (Table 3). Among
the 23 patients treated with consolidation docetaxel, the
response rate was 56.5% (95% CI, 36.9–75.1). Three patients
had progressive disease after CMT and were not evaluable for
response after consolidation. For all 26 eligible patients,
median progression-free survival was 10.7 months (95% CI,
5.36–16), and median survival was 27.8 months (22.1–33).
The 1- and 2-year survival rates were 61.5% (95% CI,
42.2–79.7), and 46.2% (95% CI, 26.8–65.2), respectively.
DISCUSSION
To our knowledge, this is the first trial in NSCLC that
evaluates the use of myeloid growth factors in patients
receiving CMT. Our study demonstrates that the addition of
filgrastim to CT and TRT is safe and effective. The rates of
grade 3⁄4 neutropenia and febrile neutropenia are significantly
reduced compared with prior trials using an identical regi-
men. For example, in SWOG 9504, grade 3⁄4 neutropenia was
reported in 74% of patients, including two infection-related
TABLE 2. Selected Grade 3/4 Toxicities
CMT
(n  26)
Consolidation
(n  23)
Hematological toxicities
Neutropenia 6 (23%) 0
Anemia 2 (7.7%) 1 (4.3%)
Thrombocytopenia 4 (15.3%) 0
Non-hematological toxicities
Pneumonitis 0 5 (21.6%)
Esophagitis 2 (7.7%) 0
Fluid retention 0 1 (4.3%)
Infection, sepsis, FN 0 0
Dose adjustments (reductions/delays) 3 (11.5%) 13 (50%)
CMT, combined modality therapy.
TABLE 3. Efficacy Parameters
CMT/Consolidation (n  26)
Best response (%) 58
Median PFS (months) 10.7
Median survival (months) 27.8
1-yr survival (%) 61.5
2-yr survival (%) 46.2
PFS, progression-free survival.
TABLE 1. Patient Characteristics
Total (n  26)
Gender
Male 20 (76%)
Female 6 (24%)
Age, median (range) 67 (50–81)
Age, 70 9 (35%)
Histological type
Adenocarcinoma 11 (42%)
Others 15 (52%)
ECOG performance status
0 10 (38%)
1 16 (62%)
Stage of disease
IIIA 15 (58%)
IIIB 11 (42%)
Journal of Thoracic Oncology • Volume 5, Number 6, June 2010 CMT With Myeloid Growth Factors in Stage III NSCLC Patients
Copyright © 2010 by the International Association for the Study of Lung Cancer 839
deaths.4 In the more recent HOG trial, during chemoradio-
therapy, grade 3⁄4 neutropenia and FN were reported in 32%
and 10% of patients, respectively.5 Finally, in a more recent
SWOG trial (SWOG 0023), using the same concurrent regi-
men, grade 3⁄4 neutropenia was noted in 43% of patients.6
Information on dose adjustments was not reported in these
studies. In our study, dose intensity was preserved, and no
deaths occurred as a consequence of CMT.
We observed grade 3⁄4 thrombocytopenia in 15% of
patients, which is high, but still within the range observed in
other studies, such as 7% in SWOG 9504, 11% in the HOG
trial, and 10% in SWOG 0023. Two patients required a
transfusion, but none had significant bleeding. Although it is
possible, and perhaps likely, that mobilization of marrow
precursors by filgrastim may lead to higher rates of throm-
bocytopenia, this toxicity, when properly monitored, appears
to be largely without serious clinical consequences and, in
our opinion, does not negate the benefits of filgrastim in the
rates of neutropenia and infection. Our rate of esophagitis
was also comparable to previous studies, suggesting no ob-
vious adverse interaction between the growth factor and this
complication.
However, our rate of pneumonitis during consolidation
was worrisome. Although a contribution from with peg-
filgrastim cannot be excluded, it is unlikely. The rate of
pneumonitis with consolidation docetaxel was lower in the
HOG trial and the SWOG 0023 trial. Many patients were
unable to complete the prescribed three cycles of consolida-
tion and dose adjustments were frequent. Hence, pneumonitis
appears to be an inherent complication of consolidation
docetaxel after CMT and does not seem to have been altered
substantially by the use of growth factors. However, we
cannot conclusively exclude such a contribution. Because all
our patients had an acceptable FEV1, we could not correlate
the incidence of pneumonitis with borderline lung capacity.7
As explained above, by the time our trial was designed, the
SWOG regimen seemed as a logical choice to test our
hypothesis. Since then, consolidation docetaxel after CMT
has been shown to offer no benefit.
The most likely reasons for our favorable experience, in
contrast to the original SWOG trial, are potential differences
between filgrastim and sargramostim as first, and significant
improvements in TRT techniques achieved over the last
decade as second. Sargramostim was used in the original
SWOG trial and has broader action on precursor cells than
filgrastim, particularly with respect to macrophages, which
may account for a greater incidence and severity of inflam-
matory processes, such as esophagitis and pneumonitis. How-
ever, any significant clinical differences that may exist as a
result of these biologic differences, particularly when used in
combination with TRT, remain hypothetical and yet to be
proven in the clinical arena.8 Innovations in TRT, including
dose, fractionation, planning, and target determination have
been substantial and arguably the single most significant
advance in the management of stage III NSCLC since the
principles of CMT were laid out in the early to mid-1990s.
These improvements allow for a more precise treatment
volume, therefore minimizing potential negative interactions
between radiation and myeloid precursors.9
Although our study used a cisplatin/etoposide regimen,
our findings are of potential application to patients with
locally advanced NSCLC treated with other CT regimens and
TRT. Moreover, it is conceivable that our findings can be
extrapolated to other locally advanced malignancies treated
with combined CT and radiotherapy, and additional studies
are encouraged. Indeed, based on our experience, the RTOG-
activated a phase II trial to test the use of filgrastim with CMT
in patients with limited-stage small-cell lung cancer, where
dose intensity may play a more relevant role (RTOG 0623).
The trial, however, has been closed because of lack of accrual
and competition with the ongoing phase III intergroup trial.
In summary, despite the small size of the trial, our
experience suggests that the use of myeloid growth factors
safely abrogates neutropenia and its complications and main-
tains dose intensity during CMT in patients with locally
advanced NSCLC. This strategy merits consideration as an
adjunct to clinical trials in patients undergoing CMT.
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